{"url_path":"/sec/halo/8-k/2026-07-02/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000088-index.html","accession_number":"0001159036-26-000088","cik":"0001159036","ticker":"HALO","issuer_name":"HALOZYME THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1159036/0001159036-26-000088-index.html","primary_entity_key":"0001159036","primary_entity_name":"HALOZYME THERAPEUTICS, INC."},"word_count":124,"has_tables":true,"body_markdown":"Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n(b) On June 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced an update to its senior management structure. The company also announced the departure of Cortney Caudill as the Company’s Senior Vice President, Chief Operating Officer. The Company would like to thank Ms. Caudill for her contributions during her tenure with the Company.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n    \n\n  Halozyme Therapeutics, Inc.\n(Registrant)\n\n     \n\nDated:\nJuly 2, 2026 \nBy:\n/s/ Darren Snellgrove\n\n  Darren Snellgrove\n\n  Senior Vice President, Chief Financial Officer"}